Chronic disease management in heart failure: focus on telemedicine and remote monitoring

Paulino Alvarez 1,*, Alex Sianis 2, Jessica Brown 3, Abbas Ali 4, Alexandros Briasoulis 2

1 Section of Heart Failure & Transplantation, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
2 Department of Clinical Therapeutics, National Kapodistrian University of Athens, 15771 Attica, Greece
3 Department of Nursing, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
4 Department of Internal Medicine, University of Iowa, Iowa City, IA 52246, USA

*Correspondence: alvarep3@ccf.org (Paulino Alvarez)

DOI: 10.31083/j.rcm2202046

In the context of the COVID-19 pandemic, many barriers to telemedicine disappeared. Virtual visits and telemonitoring strategies became routine. Evidence is accumulating regarding the safety and efficacy of virtual visits to replace in-person visits. A structured approach to virtual encounters is recommended. Telemonitoring includes patient reported remote vital sign monitoring, information from wearable devices, cardiac implantable electronic devices and invasive remote hemodynamic monitoring. The intensity of the monitoring should match the risk profile of the patient. Attention to cultural and educational barriers is important to prevent disparities in telehealth implementation.

Keywords
Telemonitoring, Heart failure with reduced ejection fraction, Telemedicine, COVID-19

1. Introduction

Heart failure (HF) is a chronic disease characterized by high mortality, often associated with multiple comorbidities that require a multidisciplinary treatment approach [1–5]. Approximately 6 million adults live with HF in the United States. Assuring access of those patients to specialized care, potentially life-saving therapies, and overcoming psychosocial, economic, and geographical barriers is a significant challenge [6–10]. Health care systems have developed disease management programs organized as spoke and hub models to overcome these limitations [11]. Telemedicine and telemonitoring are an integral part of those programs, and their application increased exponentially in 2020–2021 during the COVID-19 pandemic [12, 13].

This review focuses on telemedicine’s current role in HF management and provides a practical framework for its application.

2. Telemedicine and telemonitoring in heart failure

2.1 Definitions of telemedicine, telemonitoring, and disease management program

Telemedicine entails utilization of information technology to provide medical care by enabling communication between providers in one location and a patient or provider at another site [14]. Telemedicine encounters can be asynchronous (e.g., reviewing an echocardiogram, laboratory data, or responding to a patient call) or synchronous, real-time interaction (e.g., video consultation of a patient with a left ventricular assist device in a rural area with the advanced HF cardiologist). Telemonitoring is the use of information technology to monitor patients at a distance. Telemonitoring can be continuous or intermittent and occur in the inpatient or outpatient setting [15] (Fig. 1). A disease management program (DMP) is characterized by multidisciplinary involvement of HF nurses and physicians, integrates all aspects of care and promotes adherence to clinical practice guidelines [16]. Current guidelines support the development and implementation of DMP in HF. Telemedicine usually occurs in the context of a DMP [17–19].

2.2 Telemedicine and telemonitoring in heart failure

2.2.1 Virtual visits

Intermittent patient-provider encounters characterize ambulatory patient care. Virtual visits (VV) are defined as synchronous audio/video interactions between the provider and the patient. The uptake of virtual visits as an alternative to in-person visits before the COVID 19 pandemic was relatively low. The lack of familiarity with technology, regulatory, legal, and reimbursement concerns were among the factors that hinder its widespread application. COVID -19 pandemic led to the disappearance of many of the barriers mentioned above and the rapid adoption of VV [20]. A recent HFSA statement summarizes current evidence and provides recommendations for a successful VV preparation and billing codes to assure the program’s sustainability in the pandemic context [21]. Follow-up within 14 days of a HF hospitalization is required to reduce readmissions and improve
Fig. 1. Framework for telehealth implementation. (A) Elements of Telehealth. (B) Persons involved in telemedicine exchange. (C) Timing of information exchange. (D) Types of Telemonitoring.

outcomes [22]. Recent pre-pandemic evidence shows that virtual visits may be a safe alternative to in-person visits in post-discharge follow-up [23, 24]. The frequency of VV is variable and determined by professional judgment. In the The Randomized Trial of Telephone Intervention in Chronic Heart Failure (DIAL), the phone call frequency ranged from weekly in patients with New York Heart Association (NYHA) III-IV symptoms, recent hospitalization, weight gain of more than 2 Kg, and severe edema to monthly in patients with NYHAI, not hospitalized within the previous year, ≤ 75 years and those not living alone [25]. Risk stratification tools such as Seattle Heart Failure Model may guide the intensity of telemedicine interventions [4, 26–28]. Electronic medical record capabilities such as MyChart® (Epic Systems Corporation, Verona, WI, USA) provide VV with asynchronous medical care triggered by non-urgent patient concerns. A telemedicine strategy should be tailored to the specific cultural and linguistic characteristics of the patient [29].

2.2.2 Telemonitoring interventions

After the initial or between follow-up in-person or VV encounters, monitoring strategies may help detect parameters associated with increased decompensation risk and provide the opportunity to change trajectories [30, 31]. Early detections and recognition of congestion have been the target of telemonitoring in HF. The first event of congestion is increased filling pressures, followed by autonomic adaptation, decreased intrathoracic impedance, weight gain, and symptoms [32]. Below, we will review the different parameters and strategies that are available for remote monitoring of HF patients.

2.2.3 Scale

Current guidelines recommend daily weight in patients with HF to promote self-monitoring, adjust diuretic therapy, and volume overload detection [18]. A nested case-control study showed that increases in body weight of 2 or more pounds are associated with hospitalization for HF. The weight gain begin at least one week before admission [33]. The interval between weight gain and hospitalization may preclude the prescription of therapeutic interventions, especially if there are barriers to healthcare access. Significant congestion can develop in patients without significant weight gain due to sympathetically mediated volume redistribution in acute HF [31].

2.2.4 Ambulatory blood pressure monitoring

Hypertension is one of the most frequent comorbidities in patients with HF [34] 24-hour ambulatory blood pressure monitoring analysis has shown that most HF patients have blunted blood pressure dipping during sleep [35]. The importance of blood pressure control HF outcomes is increasingly recognized [36]. Home-blood pressure management with goals <135/85 mmHg is emerging as a dominant strategy in hypertension [37]. Blood pressure should be monitored in the morning before intake of medications, using an automatic blood pressure monitor, in a quiet room after 5
min of rest, seated with their back and arm supported. The average of at least two blood pressure measurements should be recorded. Home-blood pressure-guided management of HF has two objectives. First, to detect hypotension that prevents the titration of guideline-directed medical therapy and may represent progression to advanced HF [38]. Second, to treat hypertension that may impact filling pressures and exercise capacity [39].

2.2.5 Wearables

Wearables are external sensors that capture continuous functional or physiological data. The sensors are incorporated in different form factors such as patches, clothes, or smartwatches. The sensors are connected to other platforms that transmit, collect and interpret the data [40, 41]. Data from wearables include but are not limited to heart rate, blood pressure, activity, lung water content, and arrhythmias. Data processing and analysis may help to diagnose decompensation, monitor response to treatment, and detect potential factors associated with increased risk of decompensation [42, 43].

Atrial fibrillation affects approximately ¼ of patients with heart failure. The presence of atrial fibrillation in heart failure is associated with increases in stroke risk, heart failure hospitalization, and all-cause mortality [44–46]. The Apple Heart Study that recruited 419,297 participants over eight months showed that an irregular pulse detected by a commercial smartwatch had a positive predictive value of 84% for detecting atrial fibrillation on electrocardiogram (ECG) simultaneously with a subsequent irregular pulse notification. Only 0.52% of the patients included in the study received an irregular pulse notification. Although the proportion of patients with HF was low (<4%), this technology holds promise to evaluate HF patients without an indication for electrocardiographic monitoring or cardiac implantable electronic devices (CIED) [47].

The LINK-HF study analyzed the accuracy of a wearable multiparametric sensor to predict HF hospitalization [48]. One hundred patients in the Veteran Affairs Health System were enrolled, and 74% had HF with reduced ejection fraction. The intervention consisted of a disposable multisensor patch placed on the chest that collected continuous ECG waveform, continuous 3-axis accelerometry, skin impedance, skin temperature, and information on activity and posture. Data were uploaded continuously to a cloud via a smartphone. Primary information includes heart rate, heart rate variability, arrhythmia burden, respiratory rate, gross activity, walking, sleep, body tilt, and body posture. Machine learning was used to build a model that would predict heart failure hospitalization. The platform had sensitivity between 76% and 88% and a specificity of 87% to detect heart failure hospitalization precursors with a median time between alert and admission of 6.5 days. The impact of this technology to improve outcomes remains to be tested.

The remote dielectric sensing (ReDS™, Netanya, Israel) FDA-approved system consists of two sensors located in a vest that can track lung fluid content by collecting changes in dielectric currents across the right mid-thorax. The vest, which is connected to a console, is worn 90 seconds per day [49]. The information is transmitted to the provider using a dedicated web application. The accuracy of the technique has been successfully validated against chest computed tomography. A pilot study that included 50 patients showed reduced HF admissions during the ReDS™ guided medical management compared to the pre and post ReDS™ phase [50]. However, the “Sensible Medical Innovations Lung Fluid Status Monitor Allows Reducing Readmission Rate of Heart Failure Patients” (SMILE™) randomized clinical trial was terminated by the sponsor [51]. The use of ReDS™ in the post-hospitalization setting has been reported in a non-randomized study [52].

2.2.6 Cardiac implantable electronic devices

CIED such as implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy defibrillators (CRT-D) improve survival in selected patients with HF and reduced ejection fraction and provide HF-related diagnostic information [18, 53] (Fig. 2A–C). Thoracic impedance is among the HF diagnostic parameters provided by ICD and CRT-D. Intrathoracic fluid content influences the electrical field’s impedance created by the current between the implantable pulse generator and the pacing electrode’s tip. Congestion is associated with a decrease in thoracic impedance [54, 55]. Intrathoracic impedance and intracardiac filling pressures are inversely correlated. The decline of thoracic impedance starts approximately 2 weeks before the onset of clinical congestion and has a sensitivity of 76.9% to predict HF hospitalization. Persistent low thoracic impedance is associated with increased mortality [56, 57]. The OptiVol fluid index (Medtronic Inc., Minneapolis, MN, USA) calculates the difference between a measured and a reference impedance and is inversely correlated with thoracic impedance. A value greater than 60 is associated with increased mortality [58]. In the OptiLink HF trial, OptiVol telemonitoring failed to reduce HF hospitalization or mortality in patients with advanced HF [59]. Of note less than <60% of the fluid index threshold crossings were followed by a medical contact. In a recent post-hoc exploratory analysis, patients who had a fluid threshold crossing alert and had an appropriate medical contact had a 39% relative risk reduction of the primary endpoint. This study highlight the importance of linking telemonitoring with medical interventions [60]. CorVue™ algorithm (St. Jude Medical, St. Paul, MN, USA) detects the intrathoracic impedance providing 12 daily measurements and comparing to a reference. Impedance is measured from RV ring to can and RV coil to can or LV ring to can. Poor sensitivity for worsening HF has been reported [61].

The Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure (PARTNERS) HF prospective cohort study
evaluated the hypothesis that using a combined HF diagnostic algorithm would improve the prediction of HF hospitalizations in patients with a left ventricular ejection fraction of \( \leq 35\% \), NYHA functional class III or IV symptoms who had a CRT-D. The algorithm which was developed and calibrated in an independent data set was considered positive if a patient had 2 of the following abnormal criteria during one month: long atrial fibrillation duration, rapid ventricular rate during atrial fibrillation, high (\( > 60 \)) fluid index, low patient activity, abnormal autonomic (high night heart rate or low heart rate variability), or notable device therapy (low CRT pacing or implantable cardioverter-defibrillator shocks), or if they only had a very high (\( > 100 \)) fluid index. Patients were followed every three months for a year. A positive diagnostic algorithm was triggered in 43% (298 of 694) of the patients. Patients with a positive device diagnostic increased 5.5 times the risk of admission for HF. The frequency of device evaluation influenced the predictive performance of the algorithm. The hazard ratio for HF hospitalization in semi-monthly, monthly, and quarterly assessments were 6.6, 5.5 and 3.1 respectively. The combined diagnostic algorithm was superior to thoracic impedance alone to predict HF hospitalizations. In conclusion, a monthly review of HF device diagnostic data identified patients at a higher risk of HF hospitalizations within the subsequent month.

The "INfluence of home monIToring on mortality and morbidity in heart failure patients with IMpaired lEft ventricular function (IN-TIME)" trial randomized in a 1:1 fashion 664 patients with NYHA functional class II or III, LVEF \( \leq 35\% \) and an indication for dual-chamber ICD or CRT-D to telemonitoring in addition to standard care or standard care alone. The telemonitoring intervention consisted of a daily review of CIED data by the on-site investigators and by a coordinating center that assured the awareness of the patient’s site of significant events. Ventricular and atrial tachyarrhythmia episodes, low percentage of biventricular pacing, increased frequency of ventricular extrasystoles, decreased patient activity, and abnormal intracardiac electrogram were considered significant events. The primary endpoint was worsening of a composite score at 12 months. The score includes clinical parameters evaluated by the clinician (e.g., HF hospitalizations) and the patient’s perspectives captured in a global assessment score. At the end of the study, 18.9% of patients in the telemonitoring group and 27.2% in the control group had worsened composite clinical score (\( p = 0.013; \) OR 0.63, 95% CI 0.43–0.90). The main driver of the worsened composite clinical score was higher mortality in the control group. The number of hospitalizations for worsening HF were not significantly different in the telemonitoring and control group. The authors postulate three mechanisms...
by which daily monitoring improved outcomes. First, early
detection of ventricular and atrial arrhythmias, second early
detection of suboptimal device function (e.g., decreased CRT
pacing), and third, calls to the patients also detected signifi-
cant clinical worsening. The PARTNERS HF and IN-TIME
studies suggest that in patients with symptomatic HF with
reduced ejection fraction and a CIED in place, routine and
systematic evaluation of HF diagnostics may help in the early
detection of worsening HF and improve clinical outcomes.

HeartLogic HF algorithm (Boston Scientific, Boston,
Mass, USA) incorporates information from multiple sensors
embedded in the commercially available ICD or CRT-D de-
vices [64, 65]. Information includes first and third heart
sounds, respiration rate, rapid shallow breathing index (the
ratio of respiration rate to tidal volume), thoracic impedance,
heart rate, and patient activity. Sensor changes from the pa-
tient’s baseline were calculated and aggregated in the Heart-
Logic HF index. An alert is triggered if the HeartLogic HF
index crosses a user-configurable threshold. Patients on alert
state and high NT-proBNP had a 50 fold increased risk of an
HF event [65]. The median time from alert onset to HF event
was 34 days creating the potential to intervene and reduce the
risk of hospitalization [64, 66].

2.2.7 Remote hemodynamic monitoring

2.2.7.1 Right ventricular pressure. The Chronicle (Medtronic
Inc., Minneapolis, MN, USA) system consisted of a pro-
grammable device that processed and stored information and
a transvenous lead with a pressure sensor incorporated near
its tip. The lead was positioned in the septum or right ven-
tricular outflow tract. The initial pilot study showed that
the device was safe but failed to significantly reduce hospi-
talizations and emergency or urgent care visits requiring in-
travenous therapy [67]. The sponsor terminated the pivotal
trial because of the development of lead failures in patients
included in previous trials [68].

2.2.7.2 Left atrial pressure. Left Atrial Pressure Monitoring to
Optimize Heart Failure Therapy Study (LAPTOP-HF) eval-
uated the safety and efficacy of a left atrial pressure sen-
sor monitoring. A HeartPOD implantable sensor lead (ISL
St Jude Medical Sylmar, Sylmar, CA, USA) measured the
left atrium waveform, core temperature, and the intracar-
diac electrogram. The ISL could be used as a stand-alone
system or as a part of a cardiac resynchronization defibril-
lator device. The system included a patient advisor module
(PAM) of the small phone size that powered the device and
allowed the patient to communicate with the implant. One
of the unique features of the trial was that the PAM pro-
vided interactive medical therapy adjustment recommenda-
tions according to the left atrial pressure level and the inves-
tigator’s input [69]. Although a significant reduction of HF
hospitalizations was achieved in the telemonitoring arm, the
Data Safety and Monitoring Board stopped the pivotal trial
after enrolling 486 patients because of a perceived excess of
procedure-related complications [70].

2.2.7.3 Pulmonary arterial pressure. The CardioMEMS™ (Ab-
ott Laboratories, Plymouth, MN, USA) is an FDA-approved
wireless pressure-sensitive device that uses microelectrome-
chanical systems (MEMS) technology (Fig. 2D). The mi-
icroelectromechanical system consists of a coil and pressure-
sensitive capacitor encased in a hermetically sealed silica cap-
sule covered by silicone. Two nitinol loops anchor the device
to a pulmonary artery branch. Pressures changes cause a shift
of the resonant radiofrequency that is captured by an external
antenna. The information is converted to a pressure wave-
form [71]. The CHAMPION trial included patients with HF
regardless of left ventricular ejection fraction, NYHA III with
a prior HF hospitalization. After undergoing CardioMEMSTM
implantation, patients were randomized to pulmonary artery
guided therapy and standard of care (treatment group) vs.
standard of care alone (control group).

In the hemodynamic treatment group, optovolemic state
was defined as:
- Pulmonary artery systolic pressure 15–35 mm Hg.
- Pulmonary artery diastolic pressure 8–20 mm Hg.
- Pulmonary artery mean pressure 10–25 mm Hg.

Definitions and treatment recommendations for hyperv-
olemic or hypovolemic states were provided to the investi-
gators. The trial met the safety and efficacy endpoints at six
months with a 98.6% and 100% freedom from device-related
complications and sensor failures, respectively, and a 28% risk
reduction of heart failure hospitalizations [72]. In 2016, the
investigators reported the complete follow-up results from
the CHAMPION randomized trial showing that when PA
pressure data was available to guide therapy, HF hospitaliza-
tions in the initial control group were reduced by 48% [73]
An analysis of the Medicare data showed similar reductions
in HF hospitalizations and the potential reduction in HF hos-
italizations costs [74]. The real world CardioMEMSTM ex-
perience is accumulating [75].

Circumstances that should be considered as potential con-
traindications include: The presence of a chest circumference
>165 cm; complex congenital heart disease or mechanical
right-sided heart valve replacement, hypersensitivity to as-
pirin or clopidogrel (if patients are not on anticoagulation
aspirin 81mg and clopidogrel 75 mg should be prescribed
for one month after implant); recurrent (>1) deep venous
thrombosis or pulmonary embolism and patients with ad-
vanced kidney disease with glomerular filtration rate (GFR)
<25 mL/min/1.73 m² who are non-responsive to diuretic
therapy or who are on chronic dialysis. Once the device is
implanted, an initial phase characterized by intensive medica-
tion titration is followed by a maintenance phase in which
hemodynamic data is reviewed once a week by the physi-
cian. The maintenance phase could be interrupted by an
acute phase where hypovolemia or hypervolemia is detected,
requiring acute medication changes. A remote pulmonary
pressure-guided program usually requires a dedicated nurse
or advanced practice provider with experience in heart failure supervised by a cardiologist. Administrative support is necessary for adequate billing to assure the sustainability of the program [76]. Hemodynamic-GUIDEd management of Heart Failure (GUIDE-HF) ongoing trial to evaluate the safety and efficacy of CardioMEMSTM in patients with HF and NYHA II-IV and symptomatic patients with elevated natriuretic peptides without recent heart failure hospitalization [77]. Studies are ongoing to evaluate the efficacy CardioMEMSTM to improve outcomes in patients with left ventricular assist devices. [78, 79]. The CordellaTM HF System (Endotronix Inc., Lisle, IL, USA) includes a pulmonary artery pressure sensor and a heart failure hub that records symptoms, patient engagement, and vital signs (blood pressure, heart rate, weight, oxygen saturations). This technology showed promising results in terms of safety and accuracy in the initial multicenter feasibility trial, and large pragmatic trials are ongoing [80].

3. Recent telemedicine and telemonitoring trials

A Cochrane Library systematic review of structured telephone support or non-invasive telemonitoring for patients with HF published in 2015, which included 41 randomized controlled trials, concluded that those interventions reduce the risk of all-cause mortality and HF-related hospitalizations [81]. Another systematic review using network meta-analysis technique that included 29 studies arrive at similar conclusions [82]. Herein, we discuss the findings of five studies that were not included in those reviews (Table 1, Ref. [83–87]). “Efficacy of telemedical interventional management in patients with heart failure” (TIM-HF2) was a randomized, controlled, parallel-group unmasked trial that tested a multifaceted telemonitoring intervention compared with usual care [83]. This trial built upon the TIM-HF experience that showed that remote patient monitoring compared with standard care was not associated with reducing all-cause mortality [88]. A subgroup analysis of TIM-HF showed that patients without depression or recent HF hospitalization were most likely to benefit from telemedicine interventions. The primary endpoint was the percentage of days lost due to unplanned cardiovascular hospital admissions or all-cause death. The intervention consisted of a remote Bluetooth monitoring system (Physio-Gate® PG 1000, GETEMED Medizin-und Informationstechnik AG, Teltow, Germany) that transmitted vital signs and electrocardiogram information directly to the monitoring center. The telemonitoring system consisted of four Bluetooth-equipped measuring devices: a 3-channel ECG, pulse oximeter, blood pressure monitor, and digital Scale. A proprietary custom-made software triaged the information to identify patients that required immediate attention. Patients were provided with a mobile phone to call the monitoring center in case of an emergency [89]. The percentage of days lost due to unplanned cardiovascular hospital admissions and all-cause death was 4.88% (95% CI 4.55–5.23) in the remote patient management group and 6.64% (6.19–7.13) in the usual care group (ratio 0.80, 95% CI 0.65–1.00; p = 0.0460). Most of the intervention’s benefit was reducing all-cause mortality and unplanned hospital admissions due to worsening HF. One year after stopping the intervention, there were no significant differences in the trial’s primary outcome [90].

The SUPPORT–H2 Study recruited high-risk HF patients and showed that a telemonitoring system with the capacity to contact the clinical staff failed to improve the adherence to guideline-directed medical therapy [84]. The small sample size is a limitation of this report. In “Optimization of the Ambulatory Monitoring for Patients With Heart Failure by Telecardiology” (OSICAT), patients with a history of HF hospitalization within the prior 12 months were randomized to telemonitoring or usual care. The telemonitoring intervention failed to reduce all-cause death or hospitalization for heart failure. The telemonitoring system provided an alert that nurses evaluated in working days, and if appropriate, they advised the patient to contact their general practitioner or cardiologist [85]. This contrasted with the intensive monitoring and readily available physician support of TIM-HF2. The Better Effectiveness After Transition – Heart Failure (BEAT-HF) was a negative clinical trial of post-HF hospitalization telemedicine monitoring. Of note, the telemonitoring strategy was not integrated with physician care to allow rapid medical treatment changes [86]. Finally, “The Heart Failure Readmission Intervention by Variable Early Follow-up” (THRIVE) Study showed that a structured phone interview by a pharmacist or a nurse within seven days of discharge had comparable clinical outcomes at 30 days (readmission and death) with an in-person visit with a physician [87].

4. Lessons from the COVID-19 pandemic

COVID-19 pandemic revitalized the interest in telemedicine and prompted regulatory changes needed for rapid deployment. Along with significant biotechnological advances, digital health has an established role in clinical practice [91]. A reduction of HF hospitalization was observed in early 2020 [92]. This was interpreted secondary to the patient’s fear of going to a healthcare facility. During the same period, a 154% increase in virtual visits was documented [93]. Virtual visits and telemedicine changed from being rare to become one of the primary forms of health care delivery. This transition was not done without difficulties, and health disparities became more evident [94]. For example, female sex and median household income <50,000 $ per year were independently associated with less telemedicine and video use and less video use, respectively [95]. In addition, technology literacy from providers and patients has been recognized as an additional barrier for telehealth implementation [96].
# Table 1. Recent trials of telemedicine in heart failure.

| Author (Ref.) | Year n° | Design                      | Primary endpoint                                      | Patients                                                                 | Intervention                                                                                     | Comparator                                                                                      | Outcome                                                                                      |
|---------------|---------|-----------------------------|--------------------------------------------------------|---------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| Ong [86]      | 2016 1437 | RCT                         | Readmission for any cause within 180 days after discharge | Adults hospitalized for heart failure                                    | Conducted by Registered Nurses: 1-Predischarge education; 2-Regularly schedule telephone coaching; 3-Home tele monitoring of weight, blood pressure, heart rate and symptoms | Pre-discharge education and follow up phone call                                              | No significant difference in primary outcome                                                  |
| Koehler [83]  | 2018 1571 | RCT                         | Percentage of days lost due to unplanned cardiovascular hospital admissions or death from any cause, during the individual patient follow-up time | Ambulatory patients; NYHA II or III; heart failure hospitalization within 12 months before randomization, and LVEF 45% or lower (could be higher if patients were on diuretics). Depression or recent hospitalization <7 days were key exclusion criteria | Daily transmission of bodyweight, blood pressure, heart rate, analysis of the heart rhythm, SpO2 and a self-rated health status to the tele-medical center; a definition of a patient’s risk category; patient education; and co-operation between the tele-medical center, and the patient’s general practitioner and Cardiologist | Usual Care defined as follow up in accordance with the current guidelines for the management and treatment of patients with heart failure | Percentage of days lost was statistically reduced in patients allocated to telemedicine |
| Galinier [85] | 2020 937 | RCT                         | All-cause mortality or unplanned hospitalizations at 18 months | Hospitalized for acute HF within 12 months before inclusion, had access to a landline telephon or General Packet Radio Service network | Tele-monitoring program which consisted in: (1) electronic devices transmitted weight and heart failure symptoms to a specialized system that generated alerts and communicated with the nurses (2) Educational HF component: Information pack and phone calls | Usual Care                                                                                      | No significant difference in primary outcome                                                  |
| Rahimi [84]   | 2020 101 | Two-armed partially blinded parallel RCT | Use of guideline-recommended medical therapy for chronic HF and major comorbidities, measured as a composite opportunity score | High risk heart failure patients. Defined by functional class, NT pro BNP and >10% 1-year mortality risk | Tele-monitoring system with integrated risk prediction and disease management service which provided alert and support to healthcare practitioner | Tele-monitoring system without integrated risk prediction and disease management service | No significant difference in primary outcome                                                  |
| Lee [87]      | 2020 2372 | RCT                         | Readmission for HF within 30 days after discharge       | Adults hospitalized for heart failure                                    | Structured telephone visit with a nurse or pharmacist to guide follow-up. Telephone appointments included a structured protocol enabling medication titration, laboratory ordering, and booking urgent clinic visits as needed under physician supervision | In person visit within 7 days                                                                   | No significant difference in 30-day readmission or mortality. Telemedicine visits non-inferior to in person-visits |

RCT, Randomized Controlled Trial.
5. Telemedicine in the heart failure clinic

Synchronous virtual encounters are followed by telemonitoring with or without a formal chronic disease management program [21]. For a virtual visit to be successful, there should be patient consent, and the patient should be familiar with the virtual platform. Although most insurances prefer video, the telephone is a valid and valuable option. The VV should follow a pre-defined structure. Medication review is of paramount importance. The patient can check the vital signs during the encounter and if the patient has a CIED, access the latest remote interrogation of the device. Monitoring of activity level is feasible, and if a step counter is available the average steps per day can be noted [97]. In patients with a wearable defibrillator, evaluation of daily step count and changes in body position in addition to electrophysiological parameters can be performed [98]. Use of the video capability to detect jugular venous distention or lower extremity swelling can also be helpful. Benzinger et al. [99] described the “Telehealth ten”, a patient-assisted medical examination with ten components. During the virtual encounter, the clinician guides the patient to perform a modified physical examination. An after-visit summary with the therapeutic plan and follow-up should be emailed to the patient.

The functional capacity, psychosocial factors and clinical stability dictate the intensity of monitoring. If a patient has a CIED, every effort should be made to maximize the information obtained through device interrogation. If the patient had a recent hospitalization for HF, implantation of a pulmonary arterial pressure monitoring device should be considered (Fig. 3). Of note, barriers for compliance such as financial factors, health literacy, dietary transgressions should be evaluated, and specific interventions should be implemented [100, 101].

6. Conclusions

Virtual visits have increased exponentially during the COVID-19 pandemic. Current evidence support the use of virtual visits to replace post discharge in-person visits. A structured approach is recommended by current guidelines. Tele-monitoring interventions can range from low to high complexity and should match the risk profile of the patient. Regardless of the tele-monitoring platform, the integration with clinical support for medical therapy optimization cannot be overemphasized. Racial and social disparities in telemedicine implementation have been reported and further research is needed.

Author contributions

PA, AB conceived and designed the content; JB reviewed the manuscript and contributed with graphical material; PA, AS, AA wrote the manuscript; PA, AB, supervised and prepared the final version for submission. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Acknowledgment

Thanks to all the peer reviewers for their opinions and suggestions.

Funding

This research received no external funding.

Conflict of interest

The authors declare no conflict of interest.
References

[1] Bernel S, Howard SW. Use Your Words Carefully: What is a Chronic Disease? Frontiers in Public Health. 2016; 4: 159–159.

[2] Riley JP, Masters J. Practical multidisciplinary approaches to heart failure management for improved patient outcome. European Heart Journal Supplements. 2016; 18: G43–G52.

[3] Shah KS, Xu H, Matsouka RA, Bhatt DJ, Heidenreich PA, Hernandez AF, et al. Heart Failure with Preserved, Borderline, and Reduced Ejection Fraction. Journal of the American College of Cardiology. 2017; 70: 2467–2486.

[4] Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. American Heart Journal. 2007; 154: 260–266.

[5] Fang JC, Ewald GA, Allen LA, Butler J, Westlake Canary CA, Colvin-Adams M, et al. Advanced (Stage D) Heart Failure: a Statement from the Heart Failure Society of America Guidelines Committee. Journal of Cardiac Failure. 2015; 21: 519–534.

[6] Virani Salim S, Alison A, Benjamin Emelia J, Bittencourt Marcio S, Callaway Clifton W, Carson April P, et al. Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association. Circulation. 2020; 141: e139–e596.

[7] Yancy Clyde W, Jessup M, Bozkurt B, Butler J, Carey Donald E, Colvin Monica M, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017; 136: e137–e161.

[8] Maddox TM, Januzzi JL, Allen LA, Breathrett K, Butler J, Davis LL, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues about Heart Failure with Reduced Ejection Fraction. Journal of the American College of Cardiology. 2021; 77: 772–810.

[9] White-Williams C, Rossi LP, Bittner VA, Driscoll A, Durant RW, Granger BB, et al. Addressing Social Determinants of Health in the Care of Patients with Heart Failure: a Scientific Statement from the American Heart Association. Circulation. 2020; 141: e641–e683.

[10] Nesbitt T, Doctorvaladan S, Southard JA, Singh S, Fekete A, Marie K, et al. Correlates of quality of life in rural patients with heart failure. Circulation. 2014; 7: 882–887.

[11] Huijtema AA, Harkness K, Heckman GA, McKelvie RS. The Spoke-Hub-and-Node Model of Integrated Heart Failure Care. The Canadian Journal of Cardiology. 2018; 34: 863–870.

[12] Gemini GF, Alderighi C, Rassini R, Mazanti M, Casolo G. Value of Telemonitoring and Telemedicine in Heart Failure Management. Cardiac Failure Review. 2019; 5: 86–92.

[13] Tersalvi G, Winterton D, Cioffi GM, Ghidini S, Roberto M, Biasco L, et al. Telemedicine in Heart Failure During COVID-19: A Step Into the Future. Frontiers in Cardiovascular Medicine. 2020; 7: 313.

[14] Craig J, Patterson V. Introduction to the practice of telemedicine. Journal of Telemedicine and Teleducare. 2005; 11: 3–9.

[15] Burri H. Remote follow-up and continuous remote monitoring, distinguished. Europe : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology. 2013; 15: i14–i16.

[16] Moertl D, Altenberger J, Bauer N, Berent R, Berger R, Boehmer A, et al. Disease management programs in chronic heart failure : Position statement of the Heart Failure Working Group and the Working Group of the Cardiological Assistance and Care Personnel of the Austrian Society of Cardiology. Wiener Klinische Wochenschrift. 2017; 129: 869–878.

[17] Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016; 37: 2129–2200.

[18] Yancy Clyde W, Jessup M, Bozkurt B, Butler J, Casey Donald E, Drazner Mark H, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation. 2013; 128: e240–e327.

[19] Greenhalgh T, A’Court C, Shaw S. Understanding heart failure; explaining telehealth – a hermeneutic systematic review. BMC Cardiovascular Disorders. 2017; 17: 156.

[20] Almujahil A, Givertz MM. Virtual Health during a Pandemic. Circulation: Heart Failure. 2020; 13: e007317.

[21] Gorodeski EZ, Goyal P, Cox ZL, Thibodeau JT, Reay RE, Rasmussen K, et al. Virtual Visits for Care of Patients with Heart Failure in the Era of COVID-19: A Statement from the Heart Failure Society of America. Journal of Cardiac Failure. 2020; 26: 448–456.

[22] McAlister FA, Youngson E, Kaul P, Ezekowitz JA. Early Follow-up after a Heart Failure Exacerbation. Circulation: Heart Failure. 2016; 9: e003194.

[23] Lee KK, Thomas RC, Tan TC, Leong TK, Steimle A, Go AS. The Heart Failure Readmission Intervention by Variable Early Follow-up (THRIVE) Study. Circulation: Cardiovascular Quality and Outcomes. 2020; 13: e006553.

[24] Gorodeski EZ, Moennich LA, Riaz H, Jehi L, Young JB, Tang WHW. Virtual Versus in-Person Visits and Appointment no-Show Rates in Heart Failure Care Transitions. Circulation: Heart Failure. 2020; 13: e007119.

[25] Grancelli H, Varini S, Ferrante D, Schwartzman R, Zambrano C, Soifer S, et al. Randomized Trial of Telephone Intervention in Chronic Heart Failure (DIAL): study design and preliminary observations. Journal of Cardiac Failure. 2003; 9: 172–179.

[26] Vazquez R, Bayes-Genis A, Cygankiewicz I, Pascual-Figal D, Grigorian-Shamagian L, Pavon R, et al. The MUSIC Risk score: a simple method for predicting mortality in ambulatory patients with chronic heart failure. European Heart Journal. 2009; 30: 1088–1096.

[27] Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, et al. The Seattle Heart Failure Model. Circulation. 2006; 113: 1424–1433.

[28] Goda A, Williams P, Mancini D, Lund LH. Selecting patients for heart transplantation: comparison of the Heart Failure Survival Score (HFSS) and the Seattle heart failure model (SHFM) the Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation. 2011; 30: 1236–1243.

[29] Hilty DM, Gentry MT, McKean AJ, Cowan KE, Lim RF, Lu FC. Telehealth for rural diverse populations: telebehavioral and cultural competencies, clinical outcomes and administrative approaches. mHealth. 2020; 6: 20.

[30] Brahmbhatt DH, Cowie MR. Remote Management of Heart Failure: An Overview of Telemonitoring Technologies. Cardio Failure Review. 2019; 5: 86–92.

[31] Mullens W, Damman K, Harjola V, Mebazza A, Brunner-La Rocca H, Martens P, et al. The use of diuretics in heart failure with congestion – a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 2019; 21: 137–155.

[32] Adamson PB. Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: new insights from continuous monitoring devices. Current Heart Failure Reports. 2009; 6: 287–292.

[33] Chaudhry SI, Wang Y, Concato J, Gill TM, Krumholz HM. Patterns of weight change preceding hospitalization for heart failure. Circulation. 2007; 116: 1549–1554.

[34] Drazner MH. The progression of hypertensive heart disease. Circulation. 2011; 123: 327–334.

[35] Goyal D, Macfadyen RJ, Waton RD, Lip GYH. Ambulatory blood pressure monitoring in heart failure: a systematic review. European Journal of Heart Failure. 2005; 7: 149–156.

[36] Wright J, Williamson JD, Whelton PK, Snyder JK, Sink KM,
Kario K, Shimbo D, Hoshide S, Wang J, Asayama K, Okubo T, et al. Emergence of Home Blood Pressure-Guided Management of Hypertension Based on Global Evidence. Hypertension. 2019; 74: 229–236.

Kittleson M, Hurwitz S, Shah MR, Nohria A, Lewis E, Givertz M, et al. Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. Journal of the American College of Cardiology. 2003; 41: 2029–2035.

Oh GC, Cho H. Blood pressure and heart failure. Clinical Hypertension. 2020; 26: 1.

Dunn J, Runge R, Snyder M. Wearables and the medical revolution. Personalized Medicine. 2019; 15: 429–448.

DeVore AD, Wosik J, Hernandez AF. The Future of Wearables in Heart Failure Patients. JACC. Heart Failure. 2018; 7: 922–932.

Singhal A, Cowie MR. The Role of Wearables in Heart Failure. Current Heart Failure Reports. 2020; 17: 125–132.

Sim I. Mobile Devices and Health. the New England Journal of Medicine. 2019; 381: 956–968.

Anter E, Jessup M, Callans DJ. Atrial Fibrillation and Heart Failure. Circulation. 2009; 119: 2516–2525.

Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. the American Journal of Cardiology. 2003; 91: 2D–8D.

Verma A, Kalman JM, Callans DJ. Treatment of Patients with Atrial Fibrillation and Heart Failure with Reduced Ejection Fraction. Circulation. 2017; 135: 1547–1563.

Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, et al. Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. New England Journal of Medicine. 2019; 381: 1909–1917.

Steihlik J, Schmaltz C, Bozkurt B, Nativi-Nicolau L, Wohlfahrt P, Wegerich S, et al. Continuous Wearable Monitoring Analytics Predict Heart Failure Hospitalization. Circulation: Heart Failure. 2020; 13: e006513.

Amir O, Rappaport D, Zafir B, Abraham WT. A novel approach to monitoring pulmonary congestion in heart failure: initial animal and clinical experiences using remote dielectric sensing technology. Congestive Heart Failure (Greenwich, Conn.). 2013; 19: 149–155.

Amir O, Ben-Gal T, Weinstein JM, Schlamser J, Burkhoff D, Abbos A, et al. Evaluation of remote dielectric sensing (RedS) technology-guided therapy for decreasing heart failure rehospitalizations. International Journal of Cardiology. 2017; 240: 279–284.

Abraham WT, Anker S, Burkhoff D, Cleland J, Gorodeski E, Jaarsma T, et al. Primary Results of the Sensible Medical Innovations Lung Fluid Status Monitor Allows Reducing Readmission Rate of Heart Failure Patients (smile) Trial. Journal of Cardiac Failure. 2019; 25: 938.

Lala A, Barghash MH, Giustino G, Alvarez-Garcia J, Konje S, Parikh A, et al. Early use of remote dielectric sensing after hospitalization to reduce heart failure readmissions. ESC Heart Failure. 2021; 8: 1047–1054.

Hawkins NM, Virani SA, Sperrin M, Buchan IE, McMurray JIV, Krahm AD. Predicting heart failure decompensation using cardiac implantable electronic devices: a review of practices and challenges. European Journal of Heart Failure. 2016; 18: 977–986.

Small RS, Tang WHW. Assessing Impedance in Heart Failure: from Device Diagnostics to Population Health Opportunities? Circulation. Heart Failure. 2016; 9: e002761.

Wang L. Fundamentals of intrathoracic impedance monitoring in heart failure. the American Journal of Cardiology. 2007; 99: 3G–10G.

Yu C, Wang L, Chau E, Chan RH, Kong S, Tang M, et al. Intrathoracic Impedance Monitoring in Patients with Heart Failure. Circulation. 2005; 112: 841–848.

Zile MR, Sharma V, Johnson JW, Warman EN, Baicu CF, Bennett TD. Prediction of all-Cause Mortality Based on the Direct Measurement of Intrathoracic Impedance. Circulation. Heart Failure. 2016; 9: e002543.

Tang WHW, Warman EN, Johnson JW, Small RS, Heywood JT. Threshold crossing of device-based intrathoracic impedance trends identifies relatively increased mortality risk. European Heart Journal. 2012; 33: 2189–2196.

Böhm M, Drexler H, Oswald H, Rybak B, Bosch R, Butter C, et al. Fluid status telemedicine alerts for heart failure: a randomized controlled trial. European Heart Journal. 2016; 37: 3154–3163.

Wintirch J, Pavlicek V, Brachmann J, Bosch R, Butter C, Oswald H, et al. Remote Monitoring with Appropriately Reaction to Alerts was Associated with Improved Outcomes in Chronic Heart Failure. Circulation: Arrhythmia and Electrophysiology. 2021; 14: e008693.

Palfy JA, Benezet-Mazuecos J, Martinez Milla J, Iglesias JA, de la Vieja J, Sanchez-Borque P, et al. CorVue algorithm efficacy to predict heart failure in real life: Unnecessary and potentially misleading information? Pacing and Clinical Electrophysiology : PACE. 2018; 41: 948–952.

Whellan DJ, Ousdigian KT, Al-Khatib SM, Pu W, Sarkar S, Porter CB, et al. Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients with Heart Failure) study. Journal of the American College of Cardiology. 2010; 55: 1803–1810.

Hindricks G, Taborsky M, Gliskon M, Heinrich U, Schumacher B, Katz A, et al. Implant-based multiparameter telemonitoring of patients with heart failure (in-TIME): a randomised controlled trial. Lancet. 2014; 384: 583–590.

Egolom VO, Parikh K, Lekavich C, Wosik J, Frazier-Mills C, Fedim M. Applications of the Multisensor HeartLogic Heart Failure Monitoring Algorithm during the COVID-19 Global Pandemic. JACC: Case Reports. 2020; 2: 1265–1269.

Gardner RS, Singh JP, Stancak B, Nair DG, Cao M, Schulze C, et al. HeartLogic Multisensor Algorithm Identifies Patients during Periods of Significantly Increased Risk of Heart Failure Events. Circulation: Heart Failure. 2018; 11: e004669.

Boehmer JP, Haririhan R, Devecchi FG, Smith AL, Molon G, Capucci A, et al. A Multisensor Algorithm Predicts Heart Failure Events in Patients with Implanted Devices. JACC: Heart Failure. 2017; 5: 216–225.

Bourge RC, Abraham WT, Adamson PB, Aaron M, Aranda JM, Magalski A, et al. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. Journal of the American College of Cardiology. 2008; 51: 1073–1079.

Adamson PB, Gold MR, Bennett T, Bourge RC, Stevenson LW, Trupp R, et al. Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of the Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients with Chronic Heart Failure (REDUCEHf) trial. Congestive Heart Failure. 2011; 17: 248–254.

Maurer MS, Adamson PB, Costanzo MR, Eigler N, Gilbert J, Gold MR, et al. Rationale and Design of the Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study (LAPTOF-HF) Journal of Cardiac Failure. 2015; 21: 479–488.

Abraham WT, Adamson PB, Costanzo MR, Eigler N, Gold M, Klapholz M, et al. Hemodynamic Monitoring in Advanced Heart Failure: Results from the LAPTOF-HF Trial. Journal of Cardiac Failure. 2016; 22: 940.

Adamson PB, Abraham WT, Aaron M, Aranda JM, Bourge RC, Smith A, et al. CHAMPION trial rationale and design: the long-term safety and clinical efficacy of a wireless pulmonary artery pressure monitoring system. Journal of Cardiac Failure. 2011; 17: 3–10.
Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011; 377: 658–666.

Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Baumun JG, Adamson PB. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet. 2016; 387: 453–461.

Desai AS, Bhimaraj A, Bharmi R, Jermyn R, Bhatt K, Shavell D, et al. Ambulatory Hemodynamic Monitoring Reduces Heart Failure Hospitalizations in “Real-World” Clinical Practice. Journal of the American College of Cardiology. 2017; 69: 2357–2365.

Heywood JT, Jermyn R, Shavell D, Abraham WT, Bhimaraj A, Bhatt K, et al. Impact of Practice-Based Management of Pulmonary Artery Pressures in 2000 Patients Implanted with the CardioMEMS Sensor. Circulation. 2017; 135: 1509–1517.

Abraham J, McCann PJ, Guglin ME, Bhimaraj A, Benjamin TS, Robinson MR, et al. Management of the Patient with Heart Failure and an Implantable Pulmonary Artery Hemodynamic Sensor. Current Cardiovascular Risk Reports. 2020; 14: 12.

Lindenfeld J, Abraham WT, Maisel A, Zile M, Smart F, Costanzo MR, et al. Hemodynamic-GUIDed management of Heart Failure (GUIDE-HF) American Heart Journal. 2019; 214: 18–27.

Sood P. Investigation to Optimize Hemodynamic Management of HeartMate II™ Left Ventricular Assist Device Patients Using the CardioMEMSTM Pulmonary Artery Pressure Sensor in Advanced Heart Failure. 2021. Available at: https://clinicaltrials.gov/ct2/show/NCT03247829 (Accessed: 23 June 2021).

Veenis JF, Manintveld OC, Constantinescu AA, Caliskan K, Birim O, Bekkers JA, et al. Design and rationale of haemodynamic guidance with CardioMEMS in patients with a left ventricular assist device: the HEMO-VAD pilot study. ESC Heart Failure. 2019; 6: 194–201.

Mullens W, Sharif F, Dupont M, Rothman AMK, Wijns W. Digital health care solution for proactive heart failure management with the Cordella Heart Failure System: results of the SIRONA first-in-human study. European Journal of Heart Failure. 2020; 22: 1912–1919.

Inglis SC, Clark RA, Dierckx R, Prieto-Merino D, Cleland JGF. Structured telephone support or non-invasive telemonitoring for patients with heart failure. Cochrane Database of Systematic Reviews. 2015; CD007228.

Zhu Y, Gu X, Xu C. Effectiveness of telemedicine systems for adults with heart failure: a meta-analysis of randomized controlled trials. Heart Failure Reviews. 2020; 25: 231–243.

Koehler F, Koehler K, Deckwurt O, Prescher S, Wegscheider K, Winkler S, et al. Telemedical Interventional Management in Heart Failure II (TIM-HF2), a randomised, controlled trial investigating the impact of telemedicine on unplanned cardiovascular hospitalisations and mortality in heart failure patients: study design and description of the intervention. European Journal of Heart Failure. 2018; 20: 1485–1493.

Koehler F, Koehler K, Prescher S, Kirwan B, Wegscheider K, Vetterazz E, et al. Mortality and morbidity 1 year after stopping a remote patient management intervention: extended follow-up results from the telemedical interventional management in patients with heart failure II (TIM-HF2) randomised trial. the Lancet Digital Health. 2020; 2: e16–e24.

Keesara S, Jonas A, Schulman K. Covid-19 and Health Care's Digital Revolution. New England Journal of Medicine. 2020; 382: e82.

Hall ME, Vaduganathan M, Khan MS, Papadimitriu L, Long RC, Hernandez GA, et al. Reductions in Heart Failure Hospitalizations during the COVID-19 Pandemic. Journal of Cardiac Failure. 2020; 26: 462–463.

Koonin LM, Hoobs B, Tsang CA, Leroy Z, Farris C, Julien HM, Deleener ME, et al. Telemedicine Outpatient Cardiovascular Care during the COVID-19 Pandemic. Circulation. 2020; 142: 510–512.

Zhai Y. A Call for Addressing Barriers to Telemedicine: Health Disparities during the COVID-19 Pandemic. Psychotherapy and Psychosomatics. 2021; 90: 64–66.

Burch AE, D’Souza B, Gimbel JR, Rohrer U, Masuda T, Sears S, et al. Physical activity is reduced prior to ventricular arrhythmias in patients with a wearable cardioverter defibrillator. Clinical Cardiology. 2020; 43: 60–65.

Benziger CP, Huffman MD, Swenz RN, Stone NJ. The Telehealth Ten: a Guide for a Patient-Assisted Virtual Physical Examination. The American Journal of Medicine. 2021; 134: 48–51.

Ruppman TM, Cooper JS, Mehr DR, Delgado JM, Dunbar-Jacob JM. Medication Adherence Interventions Improve Heart Failure Mortality and Readmission Rates: Systematic Review and Meta-Analysis of Controlled Trials. Journal of the American Heart Association. 2016; 5: e002606.

Gellad WF, Grenard JL, Marcum ZA. A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. The American Journal of Geriatric Pharmacotherapy. 2011; 9: 11–23.